LUCIRA HEALTH INC. overview

Lab-quality results for both COVID-19 and Flu now available at home from one single test COVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access time-sensitive prescription treatment options Lucira’s COVID-19 & Flu Home Test demonstrated similar performance for COVID-19 and Flu in head-to-head comparison study with highly sensitive lab-based PCR tests Lucira also secured point-of-care test (POCT) authorization in Australia prior to...

Lab-quality results for both COVID-19 and Flu now available at home from one single test COVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access time-sensitive prescription treatment options Lucira’s COVID-19 & Flu Home Test demonstrated similar performance for COVID-19, Flu A and Flu B in head-to-head comparison study with highly sensitive lab-based PCR tests Lucira seeks a strategic or financial partner for resumption of manufacturing...

EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company, announced today that it has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, while continuing to support its...

For $98 CAD Canadians will receive a free telehealth appointment included with purchase of a test Lucira Connect provides lab-quality at-home test-users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only the cost of the test, excluding prescription costs. Lucira partners with Medi-Call to give users who test positive for Covid-19 or Flu the option to access a virtual telehealth consultation to discuss their risk factors and appropriate treatment options...

EMERYVILLE, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health" or "Lucira"), a medical technology company, announced that it submitted an Emergency Use Authorization application to the FDA for OTC use of its simple, at-home molecular COVID-19 & Flu test. Lucira’s test for COVID-19 & Flu was granted Emergency Use Authorization for Point-of-Care (POC) use in a healthcare setting in November 2022. In seeking OTC authorization, Lucira intends to make the...

Lucira COVID-19 & Flu Test is the first and only combination over-the-counter (OTC) self-test with fast, molecular lab-quality results enabling mass testing of symptomatic residents, staff and visitors amid the aggressive COVID-19 and flu season in Canada. Lucira’s 99% accurate, differential molecular test can detect Influenza A/B and all strains of COVID-19 earlier in an infection. On-site assessment (as little as 11-mins for positive status up to 30-min for result confirmation) will minimize...

PCR Lab-quality NAAT/molecular test for both COVID-19 and flu from 1 shallow nasal swab Positive result as quickly as 11 minutes, negative result in 30 minutes, allowing diagnosis during patient visit Equipment-free Lucira platform requires no capital investment or calibration and permits unlimited simultaneous testing COVID-19 and flu have similar symptoms but different treatments, requiring a fast differential test to access time-sensitive prescription treatment options Lucira’s COVID-19 &...

Digital health service offers Lucira lab-quality at-home test users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only $29, excluding prescription costs Lucira partners with Pfizer to increase awareness of the high risk factors for severe COVID-19 and treatment options through the Lucira Connect platform EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX) today announced the launch of...